- Trials with a EudraCT protocol (176)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
176 result(s) found for: Sodium MRI.
Displaying page 6 of 9.
EudraCT Number: 2016-000187-42 | Sponsor Protocol Number: 156-12-298 | Start Date*: 2016-10-24 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind, Placebo-controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy of Tolvaptan followed by a Two Year Open-l... | |||||||||||||
Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001114-26 | Sponsor Protocol Number: M14-500 | Start Date*: 2014-11-10 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remi... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IE (Completed) GB (Completed) SE (Completed) ES (Completed) HU (Completed) IT (Completed) NL (Completed) AT (Completed) GR (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002442-45 | Sponsor Protocol Number: AXAFA-AFNET5 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:Kompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)] | ||||||||||||||||||||||||||||
Full Title: Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy. | ||||||||||||||||||||||||||||
Medical condition: Atrial fibrillation catheter ablation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Completed) AT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000620-34 | Sponsor Protocol Number: Imatinib-MS | Start Date*: 2018-04-24 | ||||||||||||||||
Sponsor Name:Department of Clinical Neuroscience, Karolinska Institutet | ||||||||||||||||||
Full Title: Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study | ||||||||||||||||||
Medical condition: Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where ther... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Prematurely Ended) NO (Prematurely Ended) DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005197-10 | Sponsor Protocol Number: VT3996-202 | Start Date*: 2021-10-01 | |||||||||||
Sponsor Name:Viracta Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) | |||||||||||||
Medical condition: Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001965-34 | Sponsor Protocol Number: oral-CORTEM | Start Date*: 2012-11-07 | |||||||||||
Sponsor Name:Servicio de Neurología, HU. Germans Trias i Pujol | |||||||||||||
Full Title: Multicenter, randomized, double-blind clinical trial to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse. | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003098-17 | Sponsor Protocol Number: SOLTI-1402 | Start Date*: 2017-03-29 |
Sponsor Name:SOLTI | ||
Full Title: CORALLEEN: A Phase 2 Clinical Trial of multi-agent Chemotherapy or letrozole plus Ribociclib (LEE001) as neoadjuvant treatment for postmenopausal patients with Luminal B/HER2-negative breast cancer. | ||
Medical condition: Luminal B/HER2-negative breast cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000781-38 | Sponsor Protocol Number: sempa1 | Start Date*: 2019-05-07 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Effect of Empagliflozin and Semaglutide on Cardio-Renal Target Organ Damage in patients with type 2 diabetes – A randomized Trial | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002106-52 | Sponsor Protocol Number: CANBiS-AD | Start Date*: 2020-03-19 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: CANnabidiol for Behavioural Symptoms in Alzheimer’s Disease | |||||||||||||
Medical condition: Alzheimer's disease patients with BPSD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002422-78 | Sponsor Protocol Number: 1 | Start Date*: 2013-10-14 | |||||||||||
Sponsor Name:University of Leicester | |||||||||||||
Full Title: Impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes: an open lable, randomised active-comparator trial. | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005450-23 | Sponsor Protocol Number: MS-LAQ-302 | Start Date*: 2008-03-17 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd | |||||||||||||
Full Title: Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad... | |||||||||||||
Medical condition: Esclerosis Múltiple Remitente Recurrente (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) EE (Completed) CZ (Completed) IT (Completed) SK (Completed) LT (Completed) BG (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020890-18 | Sponsor Protocol Number: A3921068 | Start Date*: 2011-02-25 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: AN EXPLORATORY PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO ASSESS THE EFFECTS OF TOFACITINIB (CP-690,550) ON MAGNETIC RESONANCE IMAGING ENDPOINTS, IN METHOTREXATE NAÏVE SUBJECTS WITH EA... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005166-31 | Sponsor Protocol Number: 3074K4-3340-WW | Start Date*: 2009-09-15 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer Company | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, and Double-blind Study to Evaluate the Safety of Tigecycline versus a Ceftriaxone Regimen in the Treatment of Complicated Intra-abdominal Infections and Communit... | |||||||||||||
Medical condition: Complicated Intra-Abdominal Infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) SI (Completed) GB (Completed) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003176-21 | Sponsor Protocol Number: TRIO 017 | Start Date*: 2008-12-31 | |||||||||||
Sponsor Name:Cancer International Research Group | |||||||||||||
Full Title: A phase II, open label multicenter trial of panobinostat (LBH589) monotherapy in women with HER2 negative locally recurrent or metastatic breast cancer | |||||||||||||
Medical condition: Women with HER-2 negative locally recurrent or metastatic breast cancer; | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) IE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004214-41 | Sponsor Protocol Number: LSO-OL006 | Start Date*: 2007-04-19 | |||||||||||
Sponsor Name:Light Science Oncology Inc. | |||||||||||||
Full Title: A Multicenter Multinational Phase 3 Randomized Study to Evaluate the Safety and Efficacy of Treating Colorectal Cancer Patients with Recurrent Liver Metastases using the LitxTM System plus Chemothe... | |||||||||||||
Medical condition: Patients with recurrent liver metastases from colorectal cancer who have progressed on either FOLFOX4 or FOLFIRI | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) LV (Completed) IT (Completed) DE (Completed) AT (Completed) SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001866-90 | Sponsor Protocol Number: AALL1131 | Start Date*: 2014-07-15 | |||||||||||
Sponsor Name:Children's Oncology Group | |||||||||||||
Full Title: Treatment of Patients for newly diagnoised High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine in the Very High Risk Stratum | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002997-28 | Sponsor Protocol Number: ISIS304801-CS20 | Start Date*: 2021-03-17 | |||||||||||
Sponsor Name:Akcea Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label Study of Volanesorsen (ISIS 304801) Administered Subcutaneously to Pediatric Patients with Familial Chylomicronemia Syndrome (FCS) | |||||||||||||
Medical condition: Familial Chylomicronemia Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006150-25 | Sponsor Protocol Number: 3206K1-2203-WW | Start Date*: 2008-06-24 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | |||||||||||||
Full Title: A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Sta... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) NL (Completed) BE (Completed) AT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001461-32 | Sponsor Protocol Number: OGX-011-12 | Start Date*: 2012-07-12 | ||||||||||||||||
Sponsor Name:OncoGenex Technologies Inc. | ||||||||||||||||||
Full Title: A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant ... | ||||||||||||||||||
Medical condition: Metastatic Castrate Resistant Prostate Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) CZ (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000047-41 | Sponsor Protocol Number: FDY-5301-201 | Start Date*: 2017-07-06 | |||||||||||
Sponsor Name:Faraday Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2A, Randomized, Double-Blind, Placebo- Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction | |||||||||||||
Medical condition: Acute Myocardial Infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
